Lipocine Inc (NAS:LPCN)

$ 5.06 0.2 (4.12%) Market Cap: 27.06 Mil Enterprise Value: 6.17 Mil PE Ratio: 0 PB Ratio: 1.41 GF Score: 41/100

Lipocine Inc at H.C. Wainwright Neuropsychiatry Virtual Conference Transcript
Jun 26, 2023
Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
Lipocine Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Lipocine Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Lipocine Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Lipocine Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Lipocine Inc Summary Transcript
Jul 09, 2020

Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 07:30PM GMT

Release Date Price: $18.36 (+0.93%)

Transcript

Wing Cheung Yip

H.C. Wainwright & Co, LLC, Research Division - Research Analyst

(technical difficulty) metabolic and endocrine disorders. Dr. Patel, Dr. Bruno, very good to have you with us. Please go ahead with your presentation.

Mahesh V. Patel

Lipocine Inc. - Co-Founder, Chairman, President & CEO

Thanks, Thomas. Thanks for the invitation. Good afternoon to all. I'm Mahesh Patel. I'm the President, CEO and Co-Founder of the company. I'm here to introduce you to the company and give you an update on our pipeline, and then I'll be passing over to Dr. Ben Bruno, who is our Director of Clinical Development, and he'll fill you in on the details of our liver asset programs in our pipeline.

Before we do that, some disclaimers on the forward-looking statement. I'll give you a few seconds to go over and dive straight into our pipeline. So Lipocine is a clinical stage biopharmaceutical company, with a focus on developing innovative products for metabolic and endocrine disorders. Very recently, we have branched and looked into opportunities in the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.